Chelsea’s Hypotension Drug Droxidopa Could Fill Void If FDA Pulls ProAmatine

The regulatory uncertainty surrounding Shire’s hypotension drug midodrine (ProAmatine and generics) leaves Chelsea Therapeutics International Ltd. in a good position for its newly submitted Northera (droxidopa).